Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years.

[1]  Manjulika Das.  Androgen deprivation therapy for prostate cancer. , 2017, The Lancet. Oncology.

[2]  A. Garden,et al.  Reduced feeding tube duration with intensity‐modulated radiation therapy for head and neck cancer: A Surveillance, Epidemiology, and End Results‐Medicare Analysis , 2017, Cancer.

[3]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[4]  F. Montorsi,et al.  Salvage therapy of small volume prostate cancer nodal failures: a review of the literature. , 2014, Critical reviews in oncology/hematology.

[5]  K. Kairemo,et al.  Meta-analysis of 11C-choline and 18F-choline PET/CT for management of patients with prostate cancer , 2014, Nuclear medicine communications.

[6]  F. Montorsi,et al.  Distribution of metastatic sites in patients with prostate cancer: A population‐based analysis , 2014, The Prostate.

[7]  F. Fazio,et al.  11C-Choline PET/CT Predicts Prostate Cancer–Specific Survival in Patients with Biochemical Failure During Androgen-Deprivation Therapy , 2014, The Journal of Nuclear Medicine.

[8]  C. Nanni,et al.  First Case of 18F-FACBC PET/CT-Guided Salvage Retroperitoneal Lymph Node Dissection for Disease Relapse after Radical Prostatectomy for Prostate Cancer and Negative 11C-Choline PET/CT: New Imaging Techniques May Expand Pioneering Approaches , 2013, Urologia Internationalis.

[9]  T. Thompson,et al.  Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches , 2013, Oncogene.

[10]  L. Hendrix,et al.  Trends in the use of postprostatectomy therapies for patients with prostate cancer: A Surveillance, Epidemiology, and End Results Medicare analysis , 2013, Cancer.

[11]  N. Keating,et al.  Does comorbidity influence the risk of myocardial infarction or diabetes during androgen-deprivation therapy for prostate cancer? , 2013, European urology.

[12]  D. Rubello,et al.  11C-Choline PET/CT Scan in Patients With Prostate Cancer Treated With Intermittent ADT: A Sequential PET/CT Study , 2013, Clinical nuclear medicine.

[13]  D. Rubello,et al.  Choline PET or PET/CT and Biochemical Relapse of Prostate Cancer: A Systematic Review and Meta-Analysis , 2013, Clinical nuclear medicine.

[14]  V. Conteduca,et al.  The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy. , 2013, Critical reviews in oncology/hematology.

[15]  N. Lumen,et al.  Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. , 2013, Clinical genitourinary cancer.

[16]  B. Trock,et al.  The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary. , 2012, The Journal of urology.

[17]  S. Reske,et al.  Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. , 2012, The Journal of urology.

[18]  R. Thompson,et al.  Natural history of biochemical recurrence after radical prostatectomy with adjuvant radiation therapy. , 2012, The Journal of urology.

[19]  R. Bale,et al.  [18F]choline positron emission tomography in prostate cancer patients with biochemical recurrence after radical prostatectomy: influence of antiandrogen therapy – a preliminary study , 2012, Nuclear medicine communications.

[20]  U. Capitanio,et al.  Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. , 2011, European urology.

[21]  E. Antonarakis,et al.  Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database , 2011, BJU international.

[22]  M. Marzola,et al.  Androgen deprivation therapy influences the uptake of 11C-choline in patients with recurrent prostate cancer: the preliminary results of a sequential PET/CT study , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  R. Thompson,et al.  Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. , 2011, European urology.

[24]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2011, European urology.

[25]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[26]  F. Saad,et al.  Current management of castrate-resistant prostate cancer. , 2010, Current oncology.

[27]  R. Henke,et al.  First Results of [11C]choline PET/CT-Guided Secondary Lymph Node Surgery in Patients with PSA Failure and Single Lymph Node Recurrence after Radical Retropubic Prostatectomy , 2010, Urologia Internationalis.

[28]  V. Bettinardi,et al.  Predictive factors of [11C]choline PET/CT in patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Richard E. Hautmann,et al.  [11C]Choline PET/CT for Targeted Salvage Lymph Node Dissection in Patients with Biochemical Recurrence after Primary Curative Therapy for Prostate Cancer , 2008, Urologia Internationalis.

[30]  F. Montorsi,et al.  A nomogram predicting long‐term biochemical recurrence after radical prostatectomy , 2008, Cancer.

[31]  V. Bettinardi,et al.  [11C]Choline uptake with PET/CT for the initial diagnosis of prostate cancer: relation to PSA levels, tumour stage and anti-androgenic therapy , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[32]  F. Fazio,et al.  Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. , 2007, European urology.

[33]  P. Scardino,et al.  The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. , 2007, European urology.

[34]  Alan W Partin,et al.  Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.

[35]  M Bolla,et al.  EAU guidelines on prostate cancer. , 2001, European urology.

[36]  D. Chan,et al.  Natural History of Progression After PSA Elevation Following Radical Prostatectomy , 1999 .

[37]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. , 2014, European urology.

[38]  T. H. van der Kwast,et al.  EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. , 2014, European urology.

[39]  I. Tannock,et al.  The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. , 2014, European urology.

[40]  F. Montorsi,et al.  The role of choline positron emission tomography/computed tomography in the management of patients with prostate-specific antigen progression after radical treatment of prostate cancer. , 2011, European urology.